Veteran medtech industry professionals have learned how to handle the “increased pressure” associated with the sector: increased pressure from regulatory changes, from clients, and from innovation. Two significant pressures medtech companies currently are grappling with are (1) creating high-quality, next-generation cost-effective products faster, and (2) improving supply chain management for current legacy products to ensure price optimization for customers while maintaining margin improvements for stakeholders.

Intrinsic value is critical to the long-term success of any medtech enterprise, whether the exit timeline is next year or a decade down the road. Intrinsic value impacts all aspects of the organization on a daily and annual basis. Effective supply chain management is both a key part of R&D execution and a critical part of a company’s day-to-day success. Accordingly, effective supply chain management continues to be a critical driver of value that all medical device manufacturers must address consistently and proactively. 

Not surprisingly, artificial intelligence (AI) can help to better manage medtech supply chains. Optimizing supply chain management is no longer a competitive advantage but rather a necessity, particularly in the medical device industry, where global complexities are entwined with patient outcomes and regulatory compliance. Effective AI implementation is uniquely positioned to drive smarter, safer, and more agile operations for today’s product catalog as well as for bringing new innovations to market sooner. 

There are various reasons for (and advantages to) incorporating AI into supply chain management. A discussion of AI’s contributions to a company’s intrinsic value follows.

Innovation – Speed to Market

Design: To use a 90s term—Unplugged! The ability to use AI to explore alternative designs for next generation designs is now “off the charts.” However, companies must still ensure their smart manufacturing technology can reproduce the AI-enhanced design. 

DFM: Emphasizing that last sentence (above), it is critical that AI-enhanced innovation teams can help successfully transition to the Design for Manufacturing (DFM) stage. DFM is an important component in this model, and the right AI tool possibly could accomplish this task more effectively.

Materials: There are countless novel materials but only a limited number have already been tested and accepted for use in medical applications due to possible patient implications. AI can help identify an appropriate material for next-generation design and suggest some that may already be compliant or could be compliant without undergoing years of testing.

Time to market: The appropriate AI R&D solution can assist through all phases of the R&D design phases to move next-generation solutions to market sooner.

Cost effective: AI can make design processes more cost effective and more importantly, ensure that next-generation devices are price competitive while increasing product margins.

Supply Chain Operations, Delivery Performance, and Cost Optimization

Demand forecasting: AI enables predictive analytics that can process historical sales data, seasonal trends, clinical adoption rates, and external signals (think atypical pandemic data or regulatory changes). These predictive models can forecast demand with greater accuracy. For the long-term, medtech firms that minimize stockouts or excess inventory will be ahead of their competition and boost their bottom lines.

Supplier risk management: Risk management is always part of the supply chain conversation. How can companies successfully minimize supply chain risks that could negatively affect customers and patients? One of the most critical lessons from the COVID-19 pandemic was the vital importance of resiliency. AI-powered platforms can continuously monitor supplier performance, financial stability, geopolitical events, and regulatory alerts. Doing so allows procurement teams to proactively mitigate risk by identifying alternative sources before disruptions occur—critical in an industry with long lead times and single-source dependencies.

Inventory optimization: Since many medical devices and components have a limited shelf life or are patient-specific, inventory optimization is considerably challenging. AI tools can help automate dynamic safety stock settings, flag expiring or obsolete products, and enable just-in-time deliveries in a much better way than human supply chain managers.

Logistics and distribution: Machine learning algorithms can improve route planning, track temperature-sensitive shipments in real time, and anticipate delays across multimodal transportation networks. With biologics and diagnostics reagents, for example, these types of algorithms can be vital for ensuring product integrity from development to end user.

Regulatory compliance and traceability: No conversation about medtech supply chains is complete without a mention of regulatory compliance. In many ways, AI can help organizations remain compliant. For instance, AI can automatically track serial numbers, lot numbers, and device history records, helping produce fast, accurate product recalls or audits. Natural language processing (NLP) also allows AI to parse regulatory documents to stay updated on evolving compliance standards across geographies. Whether a product is already in multiple countries, or is eyeing new markets, AI can ensure that companies follow proper protocol regardless of their geographical commercialization plans. 

Despite its potential, it is not always easy to implement AI. In the medtech sector, the technology’s success in helping manage the supply chain depends heavily on data quality and integration. AI models can only generate reliable insights if they are fed with accurate, complete, timely information. There are many companies (especially those with aggressive M&A strategies) that still struggle with siloed data spread across disparate systems such as ERP, CRM, MES, and logistics platforms. Without unifying these datasets into a single source of truth, AI tools risk producing fragmented or misleading recommendations. Doing so can undermine both operational efficiency and decision-making—problems that could outright negate AI’s numerous benefits. Establishing robust data governance and integration processes is therefore a foundational step before AI can deliver its full value.

Looking ahead, AI is poised to play an increasingly strategic role in reshaping the ways in which medtech companies operate globally. One key opportunity lies in enabling firms to localize supply chains—bringing manufacturing and distribution closer to end markets—without sacrificing efficiency or cost-effectiveness. This capability will be especially critical as organizations work to navigate tariff and trade challenges. AI’s ability to analyze complex market, regulatory, and cost data in real time will help companies adapt faster and more effectively to shifting trade landscapes. If all of this is done well, companies’ intrinsic value will continue to rise, which will be attractive for all stakeholders—employees, customers, suppliers, and shareholders.

MORE FROM MEDWORLD ADVISORS: How the Medtech On-Shoring Boom is Redrawing the Supply Chain Map

Estelle Black has a decade of experience working with companies and supply chains, mostly helping organizations ensure a positive contribution to enterprise value. She is currently the Business Operations director at MedWorld Advisors and can be reached at estelleblack@medworldadvisors.com.